Cancer Clinical Trial -NiKang Therapeutics-NKT2152-101

A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Drug

Oral NKT2152

Phase

Phase I/||

Condition

Renal Cell

Keywords

HIF2α, NKT2152